These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

448 related items for PubMed ID: 16954954

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
    Hindorf U, Lyrenäs E, Nilsson A, Schmiegelow K.
    Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
    [Abstract] [Full Text] [Related]

  • 3. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
    Gisbert JP, Luna M, Maté J, González-Guijarro L, Cara C, Pajares JM.
    Hepatogastroenterology; 2006 Nov; 53(69):399-404. PubMed ID: 16795981
    [Abstract] [Full Text] [Related]

  • 4. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B.
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [Abstract] [Full Text] [Related]

  • 5. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML.
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [Abstract] [Full Text] [Related]

  • 6. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB, Barclay ML.
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
    González-Lama Y, Bermejo F, López-Sanromán A, García-Sánchez V, Esteve M, Cabriada JL, McNicholl AG, Pajares R, Casellas F, Merino O, Carpio D, Vera MI, Muñoz C, Calvo M, Benito LM, Bujanda L, García-Fernández FJ, Ricart E, Ginard D, Velasco M, Carneros JA, Manceñido N, Calvo M, Algaba A, Froilan C, Cara C, Maté J, Abreu L, Gisbert JP, "Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)".
    Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis.
    Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T.
    J Gastroenterol; 2003 Sep; 38(8):740-6. PubMed ID: 14505127
    [Abstract] [Full Text] [Related]

  • 11. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY, Devlin SM, Mirocha JM, Papadakis KA.
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [Abstract] [Full Text] [Related]

  • 12. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease.
    Navarro FA, Hanauer SB, Kirschner BS.
    J Pediatr Gastroenterol Nutr; 2007 Sep; 45(3):312-8. PubMed ID: 17873743
    [Abstract] [Full Text] [Related]

  • 13. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.
    Gazouli M, Pachoula I, Panayotou I, Mantzaris G, Syriopoulou VP, Goutas N, Vlachodimitropoulos D, Anagnou NP, Roma-Giannikou E.
    J Clin Pharm Ther; 2010 Feb; 35(1):93-7. PubMed ID: 20175817
    [Abstract] [Full Text] [Related]

  • 14. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
    Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, Klungel OH, Verbeek AL, Hooymans PM, Peters WH, te Morsche RH, Newman WG, Scheffer H, Guchelaar HJ, Franke B, TOPIC Recruitment Team.
    Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
    [Abstract] [Full Text] [Related]

  • 15. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.
    Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, Sasaki M, Saito Y, Fujiyama Y.
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1373-7. PubMed ID: 18662197
    [Abstract] [Full Text] [Related]

  • 16. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS, George PM, Florkowski CM.
    Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
    [Abstract] [Full Text] [Related]

  • 17. The efficacy of low dose azathioprine/6-mercaptopurine in patients with inflammatory bowel disease.
    Kim DU, Kim YH, Kim BJ, Chang DK, Son HJ, Rhee PL, Kim JJ, Rhee JC.
    Hepatogastroenterology; 2009 Oct; 56(94-95):1395-402. PubMed ID: 19950798
    [Abstract] [Full Text] [Related]

  • 18. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
    Gisbert JP, Niño P, Rodrigo L, Cara C, Guijarro LG.
    Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
    [Abstract] [Full Text] [Related]

  • 19. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
    Cao Q, Zhu Q, Shang Y, Gao M, Si J.
    Digestion; 2009 Dec; 79(1):58-63. PubMed ID: 19252404
    [Abstract] [Full Text] [Related]

  • 20. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Müller R, Schwab M.
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.